Back to Search
Start Over
Cannabinoid and nitric oxide signaling interplay in the modulation of hippocampal hyperexcitability: Study on electrophysiological and behavioral models of temporal lobe epilepsy in the rat.
- Source :
-
Neuroscience [Neuroscience] 2015 Sep 10; Vol. 303, pp. 149-59. Date of Electronic Publication: 2015 Jun 29. - Publication Year :
- 2015
-
Abstract
- A growing bulk of evidence suggests that cannabinoid system plays a pivotal role in the control of hyperexcitability phenomena. Notwithstanding, the anticonvulsant action of cannabinoids has not been fully addressed, in particular the involvement of potential cellular neuromodulators, for instance nitric oxide. In the current study, we focused on two distinct rat models of temporal lobe epilepsy, the Maximal Dentate Activation and the pilocarpine-induced acute seizures, providing both electrophysiological and behavioral data on cannabinoid and nitrergic system interplay. We evaluated the antiepileptic effects of WIN 55,212-2, (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl) pyrrolo[1,2,3-de]-1,4-benzoxazin-6-Yl]-1-naphthalenylmethanone (WIN), a CB agonist, and of 7-Nitroindazole (7NI), a preferential neuronal nitric oxide synthase (nNOS) inhibitor, at different doses, alone and in combination. MDA study showed that these drugs protected animals in a dose-dependent manner from electrically induced epileptiform discharges. In pilocarpine model, a dose-related activity of 7NI and WIN: a) decreased the behavioral scoring, used to describe the severity of chemically induced acute seizures; b) affected latency of the onset of acute convulsions; c) dampened mortality rate. Interestingly, the combination of the treatments brought to light that individually ineffective doses of WIN turn into effective when nNOS activity is pharmacologically inhibited in both experimental conditions. This effect is mediated by CB1 receptor since the co-administration of N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (AM251), a CB1 receptor specific antagonist, thwarted the 7NI-WIN convergent action. In the light of this, our findings suggest a putative antagonism between CBr-activated pathway and NO signaling in the context of neuronal hyperexcitability and contribute to elucidate possible synaptic processes underlying neuroprotective properties of cannabinoids, with a view to better integrate antiepileptic therapy.<br /> (Copyright © 2015 IBRO. Published by Elsevier Ltd. All rights reserved.)
- Subjects :
- Animals
Benzoxazines pharmacology
Cannabinoid Receptor Agonists pharmacology
Disease Models, Animal
Dose-Response Relationship, Drug
Epilepsy, Temporal Lobe chemically induced
Hippocampus physiopathology
Indazoles pharmacology
Male
Morpholines pharmacology
Naphthalenes pharmacology
Nitric Oxide Synthase antagonists & inhibitors
Pilocarpine
Piperidines pharmacology
Pyrazoles pharmacology
Rats
Rats, Wistar
Receptor, Cannabinoid, CB1 antagonists & inhibitors
Receptor, Cannabinoid, CB1 metabolism
Cannabinoids metabolism
Epilepsy, Temporal Lobe metabolism
Hippocampus metabolism
Nitric Oxide metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1873-7544
- Volume :
- 303
- Database :
- MEDLINE
- Journal :
- Neuroscience
- Publication Type :
- Academic Journal
- Accession number :
- 26135674
- Full Text :
- https://doi.org/10.1016/j.neuroscience.2015.06.047